Eric Venker Sells 177,704 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

On December 30, 2024, Eric Venker, the Chief Operating Officer of Roivant Sciences Ltd. (NASDAQ:ROIV), completed the sale of 177,704 shares of the company's stock. The shares were sold at an average price of $11.54 each, totaling a transaction value of $2,050,704.16. Following this sale, Venker retains ownership of 740,976 shares, which are currently valued at approximately $8,550,863.04. This reduction in shares represents a 19.34% decline in his overall position.

This transaction was reported in a legal filing with the SEC, which provides detailed disclosures on insider trades. Interested parties can access this information through appropriate channels.

In addition to the recent sale, Eric Venker has made other notable trades, including:

• On December 27, 2024, Venker sold 176,900 shares at an average price of $11.82, amounting to $2,090,958.00.
• On December 20, 2024, he sold 100,000 shares at an average price of $11.49 for a total of $1,149,000.00.
• On November 20, 2024, 100,000 shares were sold at an average price of $11.32, totaling $1,132,000.00.
• Additionally, on October 21, 2024, he sold 100,000 shares at an average price of $11.65, which came to $1,165,000.00.

Roivant Sciences Stock Performance

As of Thursday, shares of Roivant Sciences (NASDAQ: ROIV) opened at $11.83. The stock displays a 50-day moving average price of $11.91 and a 200-day moving average of $11.55. Over the past year, the stock has reached a low of $9.69 and a high of $13.06. Roivant Sciences has a market capitalization of approximately $8.61 billion, a price-to-earnings (PE) ratio of 2.09, and a beta of 1.25, reflecting its volatility compared to the market.

Institutional Trading Dynamics

Recent activities among hedge funds indicate changes in their positions regarding Roivant Sciences. nVerses Capital LLC established a new stake valued around $34,000 in the second quarter, while Gladius Capital Management LP bought shares worth about $35,000 in the third quarter. Also, Point72 Hong Kong Ltd entered the stock with a new stake valued at approximately $36,000 in the second quarter.

US Bancorp DE notably increased its stake by 146.5% in the third quarter, acquiring 3,278 shares valued at $38,000 after purchasing an additional 1,948 shares last quarter. Quarry LP also invested in new shares estimated at approximately $53,000 during the second quarter. As it stands, institutional investors and hedge funds collectively own 64.76% of Roivant Sciences stock.

Analyst Perspectives

Several analysts have assessed Roivant Sciences recently. Bank of America raised its price target from $12.00 to $12.50 and assigned the company a “neutral” rating as of September 11, 2024. HC Wainwright maintained a “buy” rating, setting a price target of $18.00 in a report dated November 13, 2024. Furthermore, Cantor Fitzgerald retained an “overweight” rating on the stock since a report was issued on September 19, 2024. Among analysts, one has assigned a hold rating while seven have given a buy rating. The consensus rating for the company is categorized as a “Moderate Buy” along with a price target expectation of $17.93.

About Roivant Sciences

Roivant Sciences Ltd. is a commercial-stage biopharmaceutical entity engaged in the development and commercialization of medications in the fields of inflammation and immunology. The company has developed a business model known as Vants, which focuses on advancing and promoting biopharmaceuticals, emerging companies in drug discovery, and health tech startups.

Eric, Venker, Roivant